Calidi biotherapeutics Review

About Calidi biotherapeutics

Calidi Biotherapeutics: Revolutionizing Cancer Treatment with Oncolytic Viruses

Cancer is one of the deadliest diseases that has plagued humanity for centuries. Despite significant advancements in medical science, cancer remains a formidable challenge for researchers and clinicians alike. However, there is hope on the horizon, thanks to companies like Calidi Biotherapeutics that are dedicated to finding a cure for cancer.

Calidi Biotherapeutics is a biotechnology company that specializes in developing oncolytic viruses (OVs) as a novel approach to treating cancer. OVs are viruses that selectively infect and kill cancer cells while sparing healthy cells. This makes them an attractive alternative to traditional chemotherapy and radiation therapy, which can cause severe side effects due to their non-specific toxicity.

The mission of Calidi Biotherapeutics is simple yet ambitious: to find the cure for cancer by delivering OVs that are designed to attack cancer. The company's approach involves using genetically modified viruses that have been engineered to target specific types of cancer cells based on their unique molecular signatures.

One of the key advantages of OVs is their ability to stimulate an immune response against tumors. When OVs infect cancer cells, they trigger an immune response that helps the body recognize and attack other tumor cells throughout the body. This makes them particularly effective against metastatic cancers, which have spread beyond their original site.

Calidi Biotherapeutics has developed several proprietary OV platforms based on different types of viruses such as adenovirus, herpes simplex virus (HSV), and vaccinia virus. Each platform has its own unique features and capabilities, allowing them to target different types of cancers with varying degrees of specificity.

For example, Calidi's lead product candidate CB-10-01 is based on an adenovirus platform and has shown promising results in preclinical studies against various solid tumors such as breast cancer, lung cancer, pancreatic cancer, and melanoma. CB-10-01 works by targeting a protein called CD46 that is overexpressed in many types of cancers but not in normal tissues.

Another product candidate under development at Calidi Biotherapeutics is CB-11-01 based on HSV platform which targets glioblastoma multiforme (GBM), one of the most aggressive forms of brain tumors with very poor prognosis despite current standard-of-care treatments such as surgery followed by radiation therapy or chemotherapy or both combined together . GBM often recurs after initial treatment due its highly invasive nature making it difficult for surgeons remove all tumor tissue during surgery leading recurrence within months after initial treatment . CB-11-01 works by targeting another protein called nectin 1 which expressed at high levels in GBM but not normal brain tissue .

In addition to developing new OV therapies , Calidi also offers contract manufacturing services for other companies looking develop OV-based products . The company's state-of-the-art facility located San Diego California provides cGMP-compliant manufacturing services from process development through clinical trial material production .

Overall , Calidi biotherapuetics represents a promising new frontier in oncology research , offering hope where there was once only despair . With its innovative approach using genetically modified viruses designed specifically target malignant cells while leaving healthy ones intact , this company could be instrumental bringing about major breakthroughs fight against this deadly disease .